Seattle biotechnology startup Blaze Bioscience has raised $8.5 million to continue developing technologies that are designed to help surgeons more… Read More
Michelle Burris, the chief financial officer at Bothell biotechnology company OncoGenex Pharmaceuticals, has resigned from her post after disclosing a “developing… Read More
NanoString Technologies continues to rake in new capital, announcing today that it has raised $15.3 million from Morgan Stanley Expansion Capital… Read More
Resolve Therapeutics, a 2-year-old Seattle biotechnology spin off from the University of Washington, has raised $5.8 million in new financing… Read More
VLST Corp., a Seattle biotech developing therapeutics for the treatment of autoimmune and inflammatory diseases, has raised an additional $5… Read More
Another day, another executive departure from RealNetworks. Yesterday, we reported that chief financial officer Michael Eggers — a 14-year veteran… Read More
Theraclone Sciences, a Seattle biotechnology company that’s developing a method to rapidly identify disease-fighting antivbodies, has attracted $10.6 million. Investors… Read More